|
2026 Journal Article Patient, carer and healthcare professionals’ perspectives of electronic patient-reported outcome measures in cancer care: A qualitative explorationTrevethan, Megan, Rammant, Elke, Brown, Amy, Brown, Bena, Williams, Fiona Crawford, Doupain, Kerrie, Eastgate, Melissa, Girgis, Afaf, McGuire, Peter, Martin, Karen, Hartel, Gunter, Miller, Elizabeth, Sabesan, Sabe, Sanmugarajah, Jasotha, Wishart, Laurelie R., Wyld, David, Webb, Penelope M., Chan, Raymond and Packer, Rebecca (2026). Patient, carer and healthcare professionals’ perspectives of electronic patient-reported outcome measures in cancer care: A qualitative exploration. European Journal of Oncology Nursing, 85 103330, 1-9. doi: 10.1016/j.ejon.2026.103330 |
|
2026 Journal Article Multifactorial Contributors to Dose Limiting and Post-Treatment Neurologic Toxicity During Chemotherapy TreatmentLi, Tiffany, Timmins, Hannah C., Horvath, Lisa G., Harrison, Michelle, Grimison, Peter, Friedlander, Michael, Marx, Gavin, Boyle, Frances, Wyld, David, Henderson, Robert D., King, Tracy, Baron-Hay, Sally, Kiernan, Matthew C., Barnes, Elizabeth H., Goldstein, David and Park, Susanna B. (2026). Multifactorial Contributors to Dose Limiting and Post-Treatment Neurologic Toxicity During Chemotherapy Treatment. Neurology, 107 (8) e218599, e218599-e218599. doi: 10.1212/wnl.0000000000218599 |
|
2026 Journal Article How equity in cancer services has been defined and measured, and why it matters: a scoping review of Universal Health Coverage systemsScanlon, Brighid, Roberts, Natasha, Wyld, David, Durham, Jo, Ling, Suping and Rachet, Bernard (2026). How equity in cancer services has been defined and measured, and why it matters: a scoping review of Universal Health Coverage systems. Global Health Action, 19 (1) 2733814, 1-19. doi: 10.1080/16549716.2026.2733814 |
|
2026 Journal Article Institutional factors associated with equitable cancer care provision for culturally and linguistically diverse populations in Queensland, Australia: a critical race theory analysisScanlon, Brighid, Roberts, Natasha, Wyld, David, Toloo, Ghasem Sam and Durham, Jo (2026). Institutional factors associated with equitable cancer care provision for culturally and linguistically diverse populations in Queensland, Australia: a critical race theory analysis. Journal of Racial and Ethnic Health Disparities, 13 (4), 3026-3040. doi: 10.1007/s40615-025-02477-8 |
|
2026 Conference Publication EFFICACY AND SAFETY OF RETREATMENT PRRT-A MULTICENTRE AUSTRALIAN STUDYChan, David, Kong, Grace, Lim, Jennifer, Grover, Piyush, Gopinathan, Piria, Brand, Holy, Chew, Rebekah, Lan, Lillian, Cehic, Gabrielle, Ransom, David, Mkhtar, Sara, Alipour, Ramin, Kashyap, Raghava, Mercurio, Jessica, Bailey, Dale, Wyld, David and Pavlakis, Nick (2026). EFFICACY AND SAFETY OF RETREATMENT PRRT-A MULTICENTRE AUSTRALIAN STUDY. HOBOKEN: WILEY. |
|
2026 Journal Article Retrospective cohort study of treatment patterns and outcomes for patients with locally advanced rectal cancer across three metropolitan hospitals in BrisbaneMacilwraith, Philip, Turner, Cassie, Roberts, Kate, Bigby, Kieron, Kang, Sebastian, Wyld, David, Burge, Matthew and Eastgate, Melissa (2026). Retrospective cohort study of treatment patterns and outcomes for patients with locally advanced rectal cancer across three metropolitan hospitals in Brisbane. Asia-Pacific Journal of Clinical Oncology. doi: 10.1111/ajco.70124 |
|
2026 Journal Article [177Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: the AGITG CONTROL NETS Multi-centre randomized trialChan, David L., Sjoquist, Katrin Marie, Ransom, David Turner, Wyld, David, Wilson, Kate, Gebski, Val, Murray, James, Kiberu, Andrew Ddembe, Burge, Matthew E., Macdonald, William, Roach, Paul, Pattison, David A., Butler, Patrick, Price, Timothy Jay, Michael, Michael, Lawrence, Benjamin James, Bailey, Dale L., Leyden, John, Leyden, Simone, Zalcberg, John Raymond, Turner, J. Harvey and Pavlakis, Nick (2026). [177Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: the AGITG CONTROL NETS Multi-centre randomized trial. European Journal of Cancer, 241 116781, 1-8. doi: 10.1016/j.ejca.2026.116781 |
|
2026 Journal Article A qualitative approach to understanding quality symptom management in routine oncology outpatient care: phase 1 of the symptom pathways projectRoberts, Natasha A., Maresco-Pennisi, Diane, Boyte, Francesca, Smith, Michael, Jacmon, Helene and Wyld, David (2026). A qualitative approach to understanding quality symptom management in routine oncology outpatient care: phase 1 of the symptom pathways project. Supportive Care in Cancer, 34 (4) 402. doi: 10.1007/s00520-026-10541-0 |
|
2026 Conference Publication Phase 2 expansion study of 212 Pb-ADVC001 in metastatic prostate cancer: the TheraPb trialHansen, Aaron Richard, Goh, Jeffrey C., Pattison, David A., Ngai, Stanley, Gan, Chun Loo Loo, Katchel, Loren, Brady, Jasmine, Kuchel, Anna, Latter, Melissa, Mason, Robert, Santoro, Paola, Crumbaker, Megan, Baronet, Meghan C., Grace, Reilly, Brilhante, Joana, Kryza, Thomas, Kuan, Kevin, Wiegert, Erol, Karmann, Anna and Wyld, David (2026). Phase 2 expansion study of 212 Pb-ADVC001 in metastatic prostate cancer: the TheraPb trial. 2026 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 26-28 February 2026. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2026.44.7_suppl.tps280 |
|
2026 Conference Publication P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs)Mak, Blossom, Tran, Ben, Thomas, Hayley, Walker, Rick, Pashankar, Farzana, Feldman, Darren R., Hansen, Aaron Richard, Huddart, Robert A., Dunwoodie, Elaine, Wheater, Matthew, Stevanovic, Amanda Gwendolyn, Mazhar, Danish, Lawrence, Nicola Jane, Birtle, Alison Jane, Oladipo, Olabode, Wyld, David, Balagtas, Jay Michael S., Stockler, Martin R. and Grimison, Peter S. (2026). P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs). Journal of Clinical Oncology, 44 (7_suppl), TPS623-TPS623. doi: 10.1200/JCO.2026.44.7_suppl.TPS623 |
|
2026 Conference Publication Results from the Phase 1b Dose Escalation of 212Pb-ADVC001 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) and novel 212Pb PET Clinical ImagingHansen, Aaron R, Ngai, Stanley, Goh, Jeffrey C., Wyld, David, Gan, Chun Loo, Katchel, Loren, O'Mahoney, Eoin, Griffiths, Matthew R., Brady, Jasmine, Kuchel, Anna, Latter, Melissa, Mason, Robert, Santoro, Paola, Crumbaker, Megan, Baronet, Meghan C., Grace, Reilly, Brilhante, Joana, Rose, Stephen, Kryza, Thomas, Kuan, Kevin, Wiegert, Erol, Karmann, Anna and Pattison, David A. (2026). Results from the Phase 1b Dose Escalation of 212Pb-ADVC001 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) and novel 212Pb PET Clinical Imaging. 13th International Symposium of Targeted ALPHA THERAPY (TAT 13), Rio de Janeiro, Brazil, 14-16 April 2026. Philadelphia, PA United States: Elsevier. doi: 10.1016/j.jmir.2026.102292 |
|
2026 Journal Article A multicenter phase II randomized controlled trial comparing 177Lu-Dotatate/capecitabine combination treatment with 177Lu-Dotatate monotherapy in patients with neuroendocrine tumorsBecx, Morticia N., Hofland, Johannes, Krenning, Eric P., Wyld, David K., Nonnekens, Julie, Verburg, Frederik A., Brabander, Tessa, van Busschbach, Jan J.V. and de Herder, Wouter W. (2026). A multicenter phase II randomized controlled trial comparing 177Lu-Dotatate/capecitabine combination treatment with 177Lu-Dotatate monotherapy in patients with neuroendocrine tumors. Clinical Cancer Research, 32 (8), OF1-OF10. doi: 10.1158/1078-0432.ccr-25-1884 |
|
2025 Conference Publication Appendiceal neuroendocrine tumours (A-NETs) in individuals aged under 50: a population-based study from Queensland, AustraliaYeung, Yong, Fard, Dratefeh Taherian, Moore, Julie and Wyld, David (2025). Appendiceal neuroendocrine tumours (A-NETs) in individuals aged under 50: a population-based study from Queensland, Australia. HOBOKEN: WILEY. |
|
2025 Conference Publication Retrospective cohort study of Treatment Patterns and Outcomes for Patients with locally advanced Rectal Cancer across Three Metropolitan Hospitals in BrisbaneMacilwraith, Philip, Turner, Cassie, Roberts, Kate, Bigby, Kieron, Kang, Sebastian, Wyld, David, Burge, Matthew and Eastgate, Melissa (2025). Retrospective cohort study of Treatment Patterns and Outcomes for Patients with locally advanced Rectal Cancer across Three Metropolitan Hospitals in Brisbane. HOBOKEN: WILEY. |
|
2025 Conference Publication Effect of Duloxetine on Quality of Life of Cancer Patients With Chemotherapy-Induced Peripheral Neuropathy: A Crossover Randomised Controlled TrialVu, Jennifer, Battaglini, Eva, Li, Tiffany, Wyld, David, Henderson, Robert, Marx, Gavin, Krishnan, Arun, Goldstein, David and Park, Susanna (2025). Effect of Duloxetine on Quality of Life of Cancer Patients With Chemotherapy-Induced Peripheral Neuropathy: A Crossover Randomised Controlled Trial. HOBOKEN: WILEY. |
|
2025 Conference Publication Effect of duloxetine on neuropathic symptom burden and objective neurophysiological parameters in chemotherapy-induced peripheral neuropathy: a crossover randomised controlled trialVu, Jennifer, Battaglini, Eva, Li, Tiffany, Wyld, David, Henderson, Robert, Marx, Gavin, Krishnan, Arun, Goldstein, David and Park, Susanna B (2025). Effect of duloxetine on neuropathic symptom burden and objective neurophysiological parameters in chemotherapy-induced peripheral neuropathy: a crossover randomised controlled trial. ANZAN Annual Scientific Meeting 2025, Brisbane, QLD Australia, 10-13 June 2025. London, United Kingdom: BMJ Group. doi: 10.1136/bmjno-2025-anzan.26 |
|
2025 Conference Publication Results from the phase Ib dose escalation of 212Pb-ADVC001 in PSMA-positive metastatic castration-resistant prostate cancer (mCRPC): The theraPb trialHansen, A.R., Pattison, D.A., Gan, C.L., Goh, J.C.H., Ngai, S., Katchel, L., Holmes, I., Baker, S., Campbell, L., Brady, J., Santoro, P., Crumbaker, M., Baronet, M., Rose, S., Adamovich, A.A., Puttick, S., Kryza, T., Kuan, K., Karmann, A. and Wyld, D.K. (2025). Results from the phase Ib dose escalation of 212Pb-ADVC001 in PSMA-positive metastatic castration-resistant prostate cancer (mCRPC): The theraPb trial. ESMO Congress 2025, Berlin, Germany, 17-21 October 2025. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2025.08.3004 |
|
2025 Conference Publication Risk factors for dose-limiting, chronic and severe chemotherapy-induced peripheral neuropathyLi, Tiffany, Timmins, Hannah C., Horvath, Lisa G., Harrison, Michelle, Grimison, Peter, Friedlander, Michael, Marx, Gavin, Boyle, Frances, Wyld, David, Henderson, Robert, King, Tracy, Baron-Hay, Sally, Kiernan, Matthew C., Barnes, Elizabeth H., Goldstein, David and Park, Susanna B. (2025). Risk factors for dose-limiting, chronic and severe chemotherapy-induced peripheral neuropathy. Australian and New Zealand Association of Neurologists Clinical Neurophysiology Workshop, Gold Coast, QLD, Australia, 6-9 October 2024. Shannon, Ireland: Elsevier. doi: 10.1016/j.clinph.2025.2110921 |
|
2025 Conference Publication Phase Ib/IIa dose escalation and expansion study of 212Pb-ADVC001 in metastatic castration-resistant prostate cancer (mCRPC): TheraPb-Phase I/II Trial in ProgressGoh, Jeffrey, Pattison, David, Ngai, Stanley, Katchel, Loren, Holmes, Ingrid, Baker, Sean, Biggs, Heather, Cuscaden, Claire, Campbell, Louise, Brady, Jasmine, Lindsay, Karen, Latter, Melissa, Griffiths, Matthew, O'Mahoney, Eoin, Dhiantravan, Nattakorn, Francis, Roslyn, Rose, Stephen, Soderholm, Amelia, Baronet, Meghan, Crumbaker, Megan, Kryza, Thomas, Shakti, Stelle, Naidoo, Sheruna, Puttick, Simon, Horsfall, Aimee, Barkhausen, Christoph, Kuan, Kevin, Santoro, Paola, Skingley, Lesley ... Hansen, Aaron (2025). Phase Ib/IIa dose escalation and expansion study of 212Pb-ADVC001 in metastatic castration-resistant prostate cancer (mCRPC): TheraPb-Phase I/II Trial in Progress. 2025 ANZUP Annual Scientific Meeting, Sydney, NSW Australia, 20-22 July 2025. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. |
|
2025 Journal Article How to support participants in urogenital and prostate clinical trials: a qualitative perspectiveRoberts, Natasha A., Davis, Ian D., Wyld, David, Goh, Jeffrey, Thompson, Maxwell, Gedye, Craig and Dhillon, Haryana M. (2025). How to support participants in urogenital and prostate clinical trials: a qualitative perspective. Psycho-Oncology, 34 (7) e70214, 1-9. doi: 10.1002/pon.70214 |
